Related Experiment Video
Updated: Jul 15, 2026
Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane
Published on: March 16, 2015
In vivo-directed evolution identifies AAV-WM04 as a next-generation vector for potent and sustained hearing
Yong Tao1, Cenfeng Chu2, Zhenzhe Cheng1
1Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China; Department of Audiology & Speech-Language Pathology, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Ear Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, China.
A novel AAV2-derived capsid, AAV-WM04, efficiently targets inner hair cells (IHCs) for gene therapy. This vector shows promise for treating hereditary hearing loss by restoring auditory function with high safety and efficacy.
Area of Science:
- Gene Therapy
- Otolaryngology
- Molecular Virology
Background:
- Efficient gene delivery to cochlear inner hair cells (IHCs) is crucial for inner ear gene therapy.
- Current vectors face challenges in cell specificity and efficiency for treating hearing loss.
Purpose of the Study:
- To identify and characterize a novel adeno-associated virus (AAV) capsid for enhanced IHC transduction.
- To evaluate the efficacy and safety of the new vector for treating hereditary hearing loss.
Main Methods:
- In vivo-directed evolution of an AAV2 capsid library with 9-amino acid insertions.
- Iterative selection in adult mouse cochlea followed by next-generation sequencing.
- Transduction efficiency, tropism, and ototoxicity assessment in mouse and non-human primate models.
- Dual-AAV trans-splicing delivery of the OTOF gene in a humanized mouse model.
Main Results:
- AAV-WM04 demonstrated superior packaging efficiency and pronounced IHC tropism.
- Near-complete IHC transduction across the cochlear axis in adult mice with minimal off-target expression.
- Selective IHC transduction in non-human primates, confirming cross-species applicability.
- Efficient delivery of the OTOF gene and restoration of auditory function in a mouse model of hereditary hearing loss.
Conclusions:
- AAV-WM04 is a highly efficient and selective next-generation vector for IHC gene therapy.
- The vector exhibits safety and cross-species applicability, supporting translational potential.
- AAV-WM04 enables precision gene therapy for hereditary hearing loss, offering sustained hearing recovery.
More Related Videos
21:55Engineering and Evolution of Synthetic Adeno-Associated Virus (AAV) Gene Therapy Vectors via DNA Family Shuffling
Published on: April 2, 2012
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants
Published on: October 18, 2022